Taro Pharmaceutical Industries agreed to a $36 million settlement in a long-running class action lawsuit alleging generic drug price-fixing that resulted in a U.S. Department of Justice antitrust investigation and over $200 million in criminal penalties.

Gregg Edwards was retained by Bernstein Liebhard on behalf of investors to provide expert opinions and testimony relating to market efficiency and class-wide damages for Taro Pharmaceutical Industries common shares.

For more information on the settlement, click here.